Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2021 | Pembrolizumab plus enfortumab vedotin for bladder cancer

Neal Shore, FACS, MD, Carolina Urologic Research Center, Myrtle Beach, SC, highlights a trial combining pembrolizumab with enfortumab vedotin versus pembrolizumab alone for patients with bladder cancer. This interview took place during the 2021 Genitourinary Cancers Symposium.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.